Story perspectives

Breakthrough Cancer Treatments: NHS Boosts Survival Rates

8/22/2025

50 12

Summary

Story summary

The NHS has launched a new bladder cancer treatment using enfortumab vedotin and pembrolizumab, improving survival rates.
Patients on this therapy lived an average of 2.5 years, versus 1.5 years with chemotherapy.
Nearly 30% of patients showed no detectable cancer, up from 12.5% with chemotherapy.
The NHS is fast-tracking advanced head and neck cancer patients into the AHEAD-MERIT trial for the HPV-targeting mRNA vaccine, BNT113.
This initiative supports a shift towards precision medicine, increasing access to innovative cancer therapies.

1 of 1

Story summary

The NHS has launched a new bladder cancer treatment using enfortumab vedotin and pembrolizumab, improving survival rates.
Patients on this therapy lived an average of 2.5 years, versus 1.5 years with chemotherapy.
Nearly 30% of patients showed no detectable cancer, up from 12.5% with chemotherapy.
The NHS is fast-tracking advanced head and neck cancer patients into the AHEAD-MERIT trial for the HPV-targeting mRNA vaccine, BNT113.
This initiative supports a shift towards precision medicine, increasing access to innovative cancer therapies.